The litigation, filed by Hagens Berman Sobol Shapiro LLP, covers investors who purchased PROCEPT common stock between February 28, 2024, and February 25, 2026. According to the complaint, the company allegedly misled the market by touting strong growth while simultaneously utilizing late-quarter bulk discounts to pull forward sales. These practices reportedly created a surplus of over 10,000 units of excess field inventory, ultimately cannibalizing future revenue.
PROCEPT BioRobotics Faces Class Action Lawsuit Over Sales Practices
Investors are targeting PROCEPT BioRobotics Corporation in a new securities class action, alleging the company artificially inflated revenue figures through undisclosed bulk discount programs. The lawsuit claims that by incentivizing excess customer inventory, the firm masked weakening demand for its Aquablation therapy handpieces, leading to a significant share price collapse.
The true extent of the inventory imbalance began to emerge during a series of earnings reports. Following an initial miss in August 2025, the company eventually admitted to the inventory glut in February 2026, revealing that U.S. handpiece sales had materially exceeded actual procedure counts since early 2023. By the end of this disclosure period, PROCEPT shares had declined by more than 48% from their August 2025 levels. Hagens Berman partner Reed Kathrein noted that the investigation centers on whether management intentionally manipulated internal sales data to bypass market expectations. Investors seeking to serve as lead plaintiffs must submit their filings by September 22, 2026.
Comments (0)
No comments yet. Be the first!